Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant

- Low molecular weight heparin (LMWH) is the treatment of choice in cancer related VTE.
- Managing cancer related recurrent VTE on therapeutic anticoagulation is a challenge.
- Current guidelines recommend dose escalation of LMWH with ant-Xa monitoring.
- Combined factor Xa $_amp_$amp; factor IIa inhibitors may be an option in refractory thrombosis.